Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANVAS: Canagliflozin Cardiovascular Outcomes Study
NCT01032629Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2009
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Started Dec 2009; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01032629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032629.